Company performance
Add to research
Current Price
as of Feb 07, 2025$8.65
P/E Ratio
N/A
Market Cap
$672.66M
Description
Add to research
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Metrics
Add to research
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerKURA
- Price$8.65-1.93%
Trading Information
- Market cap$672.66M
- Float83.90%
- Average Daily Volume (1m)2,066,548
- Average Daily Volume (3m)2,194,535
- EPS-$2.36
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$54.40M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$59.68M
- EV$1.26B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B1.59
- Debt/Equity3.92
Documents
Add to research
SEC Filings
Earnings Calls
Factset Street Account